Palo is done.

Quote
The EMA said on its website that it could not draw any firm conclusions on the benefits of the French biopharma’s Sohonos (palovarotene), which selectively targets the retinoic-acid receptor gamma (RARγ), “as the applicant’s conclusion was based on a post-hoc analysis which was neither scientifically nor clinically justified and pre-specified study objectives were not met.”
 












Ipsen suffers another setback for palovarotene with negative EU opinion | FirstWord Pharma

https://firstwordpharma.com/story/5700507?aid=5700507

“The EMA noted that the pre-specified study objectives were not met, while results from other trials, along with limited long-term clinical data, do not support efficacy. The regulator also said that the possibility of premature physeal closure could not adequately be mitigated with the risk minimisation measures proposed by Ipsen. Meanwhile, the agency also suggested that some questions regarding the quality of the active substance have not been resolved.”
 






anonymous said:
Ipsen suffers another setback for palovarotene with negative EU opinion | FirstWord Pharma

https://firstwordpharma.com/story/5700507?aid=5700507

“The EMA noted that the pre-specified study objectives were not met, while results from other trials, along with limited long-term clinical data, do not support efficacy. The regulator also said that the possibility of premature physeal closure could not adequately be mitigated with the risk minimisation measures proposed by Ipsen. Meanwhile, the agency also suggested that some questions regarding the quality of the active substance have not been resolved.”
Click to expand...

Hey, look at the bright side. They didn’t seem to have a problem with the product name. That has to count for something.
 










































Doesn’t matter about Palo. Company is still controlled by jealous French leaders that wish they lived in the US. Hating on what the US offers. But they need to come to the US all the time, with ridiculous red carpet visits and slides and prep up the ass that takes away from real business. Hours spent creating decks for these clowns. They are so disconnected from the field and what’s going on out here but act like they know best. The French are colonizing their own, as a hostile takeover of power. In most pharma companies the US is strong and more powerful given market and $ potential but not here, French can’t have that. Makes their puny business line up with their dick size. How many Americans are on the leadership team in US now? Exactly. Can’t understand half of them when they speak.
 






anonymous said:
Doesn’t matter about Palo. Company is still controlled by jealous French leaders that wish they lived in the US. Hating on what the US offers. But they need to come to the US all the time, with ridiculous red carpet visits and slides and prep up the ass that takes away from real business. Hours spent creating decks for these clowns. They are so disconnected from the field and what’s going on out here but act like they know best. The French are colonizing their own, as a hostile takeover of power. In most pharma companies the US is strong and more powerful given market and $ potential but not here, French can’t have that. Makes their puny business line up with their dick size. How many Americans are on the leadership team in US now? Exactly. Can’t understand half of them when they speak.
Click to expand...

https://getyarn.io/yarn-clip/0d2e949b-6adc-40ea-8aed-e736b729f28b
 






Top Bottom
Back
Quote